Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARBs CORONA II
NCT04606563Phase 3Terminated
- Sponsor
- University of British Columbia
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of losartan, valsartan, azilsartan, candesartan, eprosartan in coronavirus disease 2019 (COVID-19), sponsored by University of British Columbia. Started Oct 2020; status: terminated.
02
Drugs
losartanvalsartanazilsartancandesartaneprosartan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04606563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606563.